Healthcare
M3, Inc.(MTHRY)
Live Price
Offline$5.03
+2.24% today
1Y Change
-28.24%
Window
Jun 25, 2025 โ Jun 15, 2026
- Market Cap
- $1.01T
- Revenue Growth
- +19.3%
- EPS Growth
- -10.6%
- Dividend Yield
- 1.2%
Coverage: 244 bars ยท Jun 25, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
M3, Inc. (MTHRY) is a Healthcare stock with a market cap of $1.01T and listed on OTC. The stock last traded around $5.03 and down 28.2% across the available one-year price window (Jun 25, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of +19.3%, EPS growth of -10.6%, a dividend yield of 1.2%. What stands out right now is revenue +19.3%, EPS -10.6%, free cash flow -15.7% with operating margin 19.9% and ROIC 8.6%. The dividend is present but secondary, with a yield around 1.2%. Valuation is more restrained than many high-expectation growth names at P/E 20.5 and price/sales 2.9. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines MTHRY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+19.3% vs +7.6% peer median
Operating Margin
Near sector median
+19.9% vs +19.4% peer median
P/E
Below sector median
20.5 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 30, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +19.3% and EPS is at -10.6%, with operating margin around 19.9%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 1.2%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -5.3% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 30, 2026 | โ | +0.8% | -5.9% | -5.7% |
2026 Feb 9, 2026 | โ | +0.4% | -7.8% | -7.3% |
2025 Oct 28, 2025 | โ | -3.5% | -2.1% | +16.8% |
Benchmark Edge
MTHRY vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
MTHRY
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
MTHRY Max Drawdown
-53.45%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for MTHRY and SPY.
Company Overview
M3, Inc.
Other OTC
M3, Inc. provides medical-related services primarily to physicians and other healthcare professionals through Internet. The company operates through five reporting segments: Medical Platform, Evidence Solution, Career Solution, Site Solution, and Overseas. It operates m3.com, a members-only Web site for providing information to the healthcare professionals; MR-kun, where member doctors can independently and continuously receive information on the m3com platform; QOL-kun that provides life support information other than medical information to members; AskDoctors, where registered doctors answer questions about health and illness from the general public; MDLinx for medical professionals in the United States; and Doctorsnetuk, a website that provides developing services for pharmaceutical companies, as well as provides drug information database in France, Germany, and Spain. The company also provides career services for doctors and pharmacists through m3com CAREER. In addition, it engages in the sales activities and marketing operations for pharmaceuticals and medical devices; development, sale, and support business of electronic medical records and medical equipment for medical institutions; survey service for medical professionals; sale and marketing support businesses for pharmaceutical companies, etc. through the Internet; provision of management support and consulting services to medical institutions, and home-visit nursing services; and provision of human resources services for healthcare professionals, as well as operates clinical trial facilities. The company was formerly known as So-netM3, Inc. and changed its name to M3, Inc. in January 2010. M3, Inc. was incorporated in 2000 and is headquartered in Tokyo, Japan.
- Leadership
- Itaru Tanimura
- IPO Date
- Jun 29, 2020
- Employees
- 12.1k
- Street Address
- Akasaka Intercity
- Mailing
- Tokyo, 107-0052
- Region
- Tokyo, JP
- Reporting Currency
- USD
- Investor Line
- 81 3 6229 8900
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 20.5
- EV/EBITDA
- 9.7
- Price/Sales
- 2.9
- Price/Book
- 2.4
Growth
- Revenue
- +19.3%
- EPS
- -10.6%
- Free Cash Flow
- -15.7%
Profitability
- Gross Margin
- 50.4%
- Operating Margin
- 19.9%
- Net Margin
- 14.4%
- ROE
- 12.7%
- ROIC
- 8.6%
Balance Sheet
- Debt/Equity
- 0.10
- Current Ratio
- 2.89
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.